Prophylactic and therapeutic immunization against protozoan infection and disease

A method for therapeutic immunization of mammal harboring a persistent Trypanosoma infection comprising:

• administering to the infected mammal a multicomponent vaccine comprising a plurality of components selected from the group consisting of
• (a) an immunogenic polypeptide and
• (b) a polynucleotide comprising a nucleotide coding region encoding an immunogenic polypeptide;
• wherein the immunogenic polypeptide comprises a Trypanosoma polypeptide comprising a glycosylphosphotidylinositol anchor attachment site, or an immunogenic fragment of said polypeptide, and wherein administration of the vaccine is effective to prevent or delay chronic debilitating disease in the mammal.

A method for therapeutic immunization of a mammal harboring a persistent Trypanosoma infection comprising:

• administering to the infected mammal a vaccine comprising at least one component selected from the group consisting of
• (a) an immunogenic polypeptide and
• (b) a polynucleotide comprising a nucleotide coding region encoding an immunogenic polypeptide,
• wherein the vaccine stimulates an antibody response, a Th1-biased CD4+ T cell response and a CD8+ T cell response against the Trypanosoma upon administration to a mammal;
• wherein the immunogenic polypeptide comprises a Trypanosoma comprising a glycosylphosphotidylinositol anchor attachment site, or an immunogenic fragment of said polypeptide;
• and wherein administration of the vaccine is effective to eliminate the parasite from the mammal.

A method for therapeutic immunization of mammal harboring a persistent Trypanosoma infection comprising:

• administering to the infected mammal a vaccine comprising at least one component selected from the group consisting of
• (a) an immunogenic polypeptide and
• (b) a polynucleotide comprising a nucleotide coding region encoding an immunogenic polypeptide,
• wherein the vaccine stimulates an antibody response, a Th1-biased CD4+ T cell response and a CD8+ T cell response against the Trypanosoma upon administration to a mammal;
• wherein the immunogenic polypeptide comprises a Trypanosoma comprising a glycosylphosphotidylinositol anchor attachment site, or an immunogenic fragment of said polypeptide;
• and wherein administration of the vaccine is effective to prevent or delay chronic debilitating disease in the mammal.

A method for prophylactic immunization of a mammal against an infectious Trypanosoma comprising:

• administering to an uninfected mammal a multicomponent vaccine comprising a plurality of components selected from the group consisting of
• (a) an immunogenic polypeptide and
• (b) a polynucleotide comprising a nucleotide coding region encoding an immunogenic polypeptide;
• wherein the immunogenic polypeptide comprises a Trypanosoma polypeptide comprising a glycosylphosphotidylinositol anchor attachment site, or an immunogenic fragment of said polypeptide;
• and wherein administration of the vaccine is effective to prevent subsequent infection of the mammal by the Trypanosoma.

A method for prophylactic immunization of a mammal against an infectious Trypanosoma comprising:

• administering to an uninfected mammal a multicomponent vaccine comprising a plurality of components selected from the group consisting of
• (a) an immunogenic polypeptide and
• (b) a polynucleotide comprising a nucleotide coding region encoding an immunogenic polypeptide;
• wherein the immunogenic polypeptide comprises a Trypanosoma polypeptide comprising a glycosylphosphotidylinositol anchor attachment site, or an immunogenic fragment of said polypeptide;
• wherein administration of the vaccine is effective to prevent the development of chronic debilitating disease the mammal after subsequent infection by the Trypanosoma.

A method for prophylactic immunization of a mammal against an infectious Trypanosoma comprising:

• administering to an uninfected mammal a multicomponent vaccine comprising a plurality of components selected from the group consisting of
• (a) an immunogenic polypeptide and
• (b) a polynucleotide comprising a nucleotide coding region encoding an immunogenic polypeptide;
• wherein the immunogenic polypeptide comprises a Trypanosoma polypeptide comprising a glycosylphosphotidylinositol anchor attachment site, or an immunogenic fragment of said polypeptide;
• wherein administration of the vaccine is effective to prevent the death of the mammal after subsequent infection by the Trypanosoma.

A method for prophylactic immunization of a mammal against an infectious Trypanosoma comprising:

• administering to an uninfected mammal a multicomponent vaccine comprising a plurality of components selected from the group consisting of
• (a) an immunogenic polypeptide and
• (b) a polynucleotide comprising a nucleotide coding region encoding an immunogenic polypeptide;
• wherein the immunogenic polypeptide comprises a Trypanosoma polypeptide comprising a glycosylphosphotidylinositol anchor attachment site, or an immunogenic fragment of said polypeptide;
• and wherein administration of the vaccine is effective to prevent subsequent infection of the mammal by the Trypanosoma.

A method for prophylactic immunization of a mammal against an infectious Trypanosoma comprising:

• administering to an uninfected mammal a multicomponent vaccine comprising a plurality of components selected from the group consisting of
• (a) an immunogenic polypeptide and
• (b) a polynucleotide comprising a nucleotide coding region encoding an immunogenic polypeptide;
• wherein the immunogenic polypeptide comprises a Trypanosoma polypeptide comprising a glycosylphosphotidylinositol anchor attachment site, or an immunogenic fragment of said polypeptide;
• and wherein administration of the vaccine is effective to prevent the development of chronic debilitating disease the mammal after subsequent infection by the Trypanosoma.

A method for prophylactic immunization of a mammal against an infectious Trypanosoma comprising:

• administering to an uninfected mammal a multicomponent vaccine comprising a plurality of components selected from the group consisting of
• (a) an immunogenic polypeptide and
• (b) a polynucleotide comprising a nucleotide coding region encoding an immunogenic polypeptide;
• wherein the immunogenic polypeptide comprises a Trypanosoma polypeptide comprising a glycosylphosphotidylinositol anchor attachment site, or an immunogenic fragment of said polypeptide;
• and wherein administration of the vaccine is effective to prevent the death of the mammal after subsequent infection by the Trypanosoma.

A method for therapeutic immunization of a mammal harboring a persistent T. cruzi infection comprising:

• administering to the infected mammal a multicomponent vaccine comprising a plurality of components selected from the group consisting of
• (a) an immunogenic T. cruzi polypeptide and
• (b) a polynucleotide comprising a nucleotide coding region encoding an immunogenic T. cruzi polypeptide wherein the immunogenic polypeptide comprises a Trypanosoma cruzi polypeptide comprising a glycosylphosphotidylinositol anchor attachment site, or an immunogenic fragment of said polypeptide;
• wherein administration of the vaccine is effective to prevent or delay chronic debilitating disease in the mammal.